Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Moderate-to-severe tricuspid regurgitation (TR) has a high prevalence in the general population, 1 and it progressively increases in older individuals, in whom it is close to 4%.

A new biological patch, designed from heart cells grown in the laboratory, could bring a glimmer of hope in the treatment of ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

The key to treating congestive heart failure is addressing the underlying causes, and treatment is highly tailored to each patient's needs. Chris Bell, an acute care nurse practitioner who specializes ...

Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

Doctors at Hue Central Hospital in Hue City, central Vietnam have successfully performed another heart transplant, saving the ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

A new study has found that severe infections such as COVID or flu increase your risk of heart failure by two times. The study ...